• Daré Bioscience initiated a Phase 2 trial of DARE-HPV, a vaginal insert designed to treat persistent high-risk HPV infection, an area with no FDA-approved drug therapies.
• Results have not been presented; a topline readout is expected in 2027.
• The study will assess whether the treatment can clear the virus and reduce the need for prolonged monitoring that often precedes surgical management of cervical disease.
• The program is supported by a USD 10 million ARPA-H contract, with USD 9 million received to date, providing non-dilutive funding as the asset moves through mid-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9721627) on May 18, 2026, and is solely responsible for the information contained therein.